Diabetic Ketoacidosis Occurring in Patient on Newly Started Insulin Glargine U300


Abstract views: 33 / PDF downloads: 18

Authors

DOI:

https://doi.org/10.5152/EurJTher.2017.293

Keywords:

Glargine U300, diabetic ketoacidosis, pharmacokinetic

Abstract

Insulin glargine U300 is a 3-fold, concentrated, long-acting insulin analog providing a more stable effect compared with insulin glargine U100. However, stable plasma insulin concentration is reached on day 4 of the treatment. Patients with type 1 and type 2 diabetes mellitus with decreased insulin reserve are at an increased risk of diabetic ketoacidosis when there is insufficient exogenous plasma insulin concentration. Herein, we present a case of diabetic ketoacidosis occurring in a patient with insulin glargine U300 and emphasize the pharmacokinetic properties of insulin glargine U300.

Metrics

Metrics Loading ...

References

Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32: 1335-43.

Kitabchi AE, Nyenwe EA. Hyperglycemic crises in diabetes mellitus: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Endocrinol Metab Clin North Am 2006; 35: 725-51.

Wang F, Zassman S, Goldberg PA. rDNA insulin glargine U300 - a critical appraisal. Diabetes Metab Syndr Obes 2016; 9: 425-41.

Wallace JP, Wallace JL, McFarland MS. Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose? Ann Pharmacother 2014; 48: 361-8.

Steinstraesser A, Schmidt R, Bergmann K, Dahmen R, Becker RH. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab 2014; 16: 873-6.

Downloads

Published

2023-04-19

How to Cite

Kıraç, C. O., İpekçi, S. H., & Kebapcılar, L. (2023). Diabetic Ketoacidosis Occurring in Patient on Newly Started Insulin Glargine U300. European Journal of Therapeutics, 24(4), 266–267. https://doi.org/10.5152/EurJTher.2017.293

Issue

Section

Case Reports